Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
6 hedge funds and large institutions have $280K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
241% more capital invested
Capital invested by funds: $82K → $280K (+$198K)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $130K | +$15.2K | +129,500 | New |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $65K | – | – | – |
|
|
PA
3
Perceptive Advisors
New York
| $46K | – | – | – |
|
|
MWNA
4
Marshall Wace North America
New York
| $20K | – | – | – |
|
|
PC
5
PointState Capital
New York
| $16K | – | – | – |
|
|
CIA
6
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $3K | – | – | – |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2K | -25,012 | Closed |
|
OTLKW Hedge Fund Activity: Q1 2020 in Review
6 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q1 2020, worth a combined $280K — up 241% from $82K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of OTLKW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $15.2K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $2K sold.
- 6 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q1 2020, down from 7 in Q4 2019.
- Funds reported $280K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q1 2020, up 241% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q1 2020 and 2 closed out, a net change of -1 holder.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q1 2020 was Sphera Funds Management, an estimated $15.2K added.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q1 2020 was Susquehanna International Group, an estimated $2K sold.
Based on aggregated 13F filings for Q1 2020.